Endocrinology drugs market size to grow by USD 36551.24 Million: Increase in the incidence of endocrine disorders remains key growth driver - Technavio
NEW YORK, Dec. 7, 2022 /PRNewswire/ -- The global endocrinology drugs market size is set to grow by USD 36551.24 million from 2022 to 2027, according to Technavio. The growth momentum of the market will accelerate at a CAGR of 7.82% during the forecast period. This report provides analysis and insights to enable effective decision-making. Download A Sample Report
Endocrinology drugs market - Key Driver and Major Challenge
The increase in the incidence of endocrine disorders is driving the endocrinology drug market growth. The prevalence of endocrine disorders such as diabetes is increasing globally, especially in low and middle-income countries. The incidence of such disorders is high in the aging population. With advances in healthcare technology, the average life expectancy of people has increased considerably across the world. This has resulted in an increase in the aging population worldwide. Thus, the rising incidence of endocrine disorders and the expanding aging population are expected to drive the growth of the global endocrinology drugs market during the forecast period.
The expiring patents of major endocrinology drugs are impeding the endocrinology drug market growth. Endocrinology drugs were available in the market since 1995, and many of the approved drugs available back then are on the verge of expiring. For instance, Lantus, one of the world's most widely prescribed insulin, lost its patent in February 2015. Similarly, NovoLog/NovoRapid's patent expired in 2014. These forthcoming patent expirations paved the way for generic drugs, resulting in the loss of market share by branded drug manufacturers. This is expected to reduce the growth potential in the market over the forecast period.
Technavio has identified key trends, drivers, and challenges, along with competitive analysis to help clients improve their strategies to stay ahead of their competitors. Buy the reportto obtain detailed insights about the market.
Major five endocrinology drugs companies
Acerus Pharmaceuticals Corp. - The company offers endocrinology drugs such as Natesto.
Bayer AG - The company offers endocrinology drugs such as finerenone.
Beta Cell NV - The company offers endocrinology drugs such as BetaGraft.
Eli Lilly and Co. - The company offers endocrinology drugs such as Humatrope.
Endo International Plc - The company offers endocrinology drugs such as fortesta.
Endocrinology Drugs Market Therapy Area Outlook (Revenue, USD mn, 2022-2027)
Diabetes drugs - size and forecast 2022-2027
HGH - size and forecast 2022-2027
Thyroid hormone disorders - size and forecast 2022-2027
Others - size and forecast 2022-2027
Endocrinology Drugs Market Distribution Channel Outlook (Revenue, USD mn, 2022-2027)
Hospital pharmacies - size and forecast 2022-2027
Retail pharmacies - size and forecast 2022-2027
Online pharmacies - size and forecast 2022-2027
Endocrinology Drugs Market Geography Outlook (Revenue, USD mn, 2022-2027)
North America - size and forecast 2022-2027
Europe - size and forecast 2022-2027
Asia - size and forecast 2022-2027
Rest of World (ROW) - size and forecast 2022-2027
Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a PDF Sample Report
What are the key data covered in this endocrinology drugs market report?
CAGR of the market during the forecast period 2023-2027
Detailed information on factors that will drive the growth of the endocrinology drugs market between 2023 and 2027
Precise estimation of the endocrinology drugs market size and its contribution to the parent market.
Accurate predictions about upcoming trends and changes in consumer behavior
Growth of the endocrinology drugs industry across North America, Europe, Asia, and the Rest of the World (ROW)
A thorough analysis of the market's competitive landscape and detailed information about vendors
Comprehensive details of factors that will challenge the growth of endocrinology drugs market vendors
Related Reports
The biosimilars market is estimated to grow at a CAGR of 23% between 2022 and 2027. The size of the market is forecast to increase by USD 42,227.12 million. The price advantage of biosimilars over biologics is notably driving the market growth, although factors such as market access barriers for biosimilars may impede the market growth.
The botanical and plant-derived drugs market size is expected to increase by USD 15.89 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 7.25%. The increase in government initiatives is notably driving the botanical and plant-derived drugs market growth, although factors such as low acceptance among physicians may impede the market growth.
Endocrinology Drugs Market Scope
Report Coverage
Details
Page number
172
Base year
2022
Historic period
2017-2021
Forecast period
2023-2027
Growth momentum & CAGR
Accelerate at a CAGR of 7.82%
Market growth 2023-2027
USD 36551.24 million
Market structure
Fragmented
YoY growth 2022-2023 (%)
6.52
Regional analysis
North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution
North America at 45%
Key countries
US, Canada, UK, Germany, and China
Competitive landscape
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled
Abbott Laboratories, Acerus Pharmaceuticals Corp., Ascendis Pharma AS, Bayer AG, Beta Cell NV, Biocon Ltd., Eli Lilly and Co., Endo International Plc, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Hanmi Pharm Co. Ltd., Ipsen Pharma, Merck and Co. Inc., Novartis AG, Novo Nordisk AS, Oramed Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., and VeroScience LLC
Market dynamics
Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period.
Customization purview
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.
Table of contents:
1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary ? Chart on Market Overview
Exhibit 02: Executive Summary ? Data Table on Market Overview
Exhibit 03: Executive Summary ? Chart on Global Market Characteristics
Exhibit 04: Executive Summary ? Chart on Market by Geography
Exhibit 05: Executive Summary ? Chart on Market Segmentation by Therapy Area
Exhibit 06: Executive Summary ? Chart on Market Segmentation by Distribution Channel
Exhibit 07: Executive Summary ? Chart on Incremental Growth
Exhibit 08: Executive Summary ? Data Table on Incremental Growth
Exhibit 09: Executive Summary ? Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2022
3.4 Market outlook: Forecast for 2022-2027
Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
4 Historic Market Size
4.1 Global endocrinology drugs market 2017 - 2021
Exhibit 18: Historic Market Size ? Data Table on Global endocrinology drugs market 2017 - 2021 ($ million)
Exhibit 180: Validation techniques employed for market sizing
Exhibit 181: Information sources
13.5 List of abbreviations
Exhibit 182: List of abbreviations
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Caledonia Mining Corporation Plc ("Caledonia" or the "Company") announces its operating and financial results for the year ended December 31, 2023 (the "Year"). Further information on the financial and operating results for the Year and the quarter...
In advance of the upcoming NAB 2024 show, fan-streaming trailblazer Attention Seekers announced that it has selected Eluvio to provide the back-end technology platform for its next-generation Keystream service, a private press streaming service...
The "United States Self-Monitoring Blood Glucose Devices Market Growth, Share, Size, Trends, Analysis and Forecast (2024 - 2032)" report has been added to ResearchAndMarkets.com's offering.
The latest comprehensive research study has been added to...
The "Highly Potent API Market - A Global and Regional Analysis: Focus on Type, Type of Synthesis, Therapeutic Area, Type of Manufacturing, End User, and Country - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's...
Akebia Therapeutics®, Inc. , a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the U.S. Food and Drug Administration (FDA)...
The "Green Hydrogen Market - A Global and Regional Analysis: Focus on Application, Technology, Renewable Energy Source, and Region - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
The global green...